Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008

ological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. Approximately 40 percent of all MS patients have the secondary progressive form of the disease.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today reported 2014 full ... key objectives, and financial guidance.  Synageva,s management team ... p.m. EST to review the financial results and ... today,s call by telephone, please dial (877) 445-4603 ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN ... its Length Gauge offerings with new variants of its ... Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge series now ... new 1Vpp, 12mm stroke length variants of the SPECTO ... a variant with a weak spring, 0.4N of gauging ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
... a failed terrorist attack in 2006, plane passengers have not ... airports, leaving some parched at the airport and others having ... in Germany is paving the way to eliminate this necessary ... in IOP Publishing,s Superconductor Science and Technology explains ...
... This release is available in German . ... the electromagnetic character of radio waves by Heinrich Hertz, wireless ... are applied to transmit more data within shorter periods of ... also be used for radio transmis-sion. So far, however, manufacture ...
... Inc. (TSX: ONC, NASDAQ: ONCY ) ("Oncolytics") announced ... Canadian Biosciences Corp. (BCBC), a privately held biotechnology company ... of a variety of conditions, including cancer. , Oncolytics ... BCBC in exchange for 200,000 common shares of Oncolytics. ...
Cached Biology Technology:0.2 second test for explosive liquids 2Smallest nanoantennas for high-speed data networks 2Smallest nanoantennas for high-speed data networks 3Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company 2
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... who has watched crime dramas on TV knows that ... from evidence gathered at a crime scene, establish a ... has been wrongly jailed. A lesser known but rapidly ... paternal ancestrya process known as genetic genealogy. The laboratories ...
... symptoms until it has spread to other organs, when it ... great promise for extending survival during later disease stages, but ... of the first discoveries of its kind, UC Davis Cancer ... own repair mechanism and, in so doing, help make chemotherapy ...
... Texas Health Science Center at Houston (UTHSC-Houston) were honored ... at the 2008 American Heart Association,s Scientific Sessions in ... killer. UT faculty members recognized were: Nobel Laureate ... Foundation Institute of Molecular Medicine for the Prevention of ...
Cached Biology News:NIST guides genetic genealogy labs toward improved accuracy 2UC Davis discovery offers hope for treating kidney cancer 2UT faculty members win American Heart Association awards for advancing research 2UT faculty members win American Heart Association awards for advancing research 3
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
TACS Apoptotic DNA Laddering Kits are used to assay cells and tissues for apoptosis by...
SHEEP ANTI HUMAN ESTRONE...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
Biology Products: